¼¼°èÀÇ ¿ø¹ß¼º ´ãÁó¼º ´ã°ü¿° ½ÃÀå ±âȸ, Àü·«(-2034³â)
Primary Biliary Cholangitis Global Market Opportunities And Strategies To 2034
»óǰÄÚµå : 1729116
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 319 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,183,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,938,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,692,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ¿ø¹ß¼º ´ãÁó¼º ´ã°ü¿° ½ÃÀå ±Ô¸ð´Â 2019³â¿¡ 7¾ï 3,321¸¸ ´Þ·¯¿¡ ´ÞÇß°í 2024³â±îÁö 5.00% ÀÌ»óÀÇ CAGRÀ» ³ªÅ¸³Â½À´Ï´Ù.

¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

°ú°ÅÀÇ ±â°£, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ¿ø¹ß¼º ´ãÁó¼º ´ã°ü¿° ½ÃÀåÀÇ ¼ºÀåÀ» Áö¿øÇß½À´Ï´Ù. ¿Àº£Æ¼ÄÝ»ê(OCA)Àº ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê(UDCA)°ú °°Àº Á¾·¡ÀÇ Ä¡·á¸¦ ´ëüÇϴ ǥÀû Ä¡·á·Î¼­ ±â´ÉÇϰí ÀÖ½À´Ï´Ù. »õ·Î¿î Ä¡·á¹ýÀº ƯÁ¤ ȯÀÚ ±×·ì¿¡ ´ëÇØ Æò°¡µË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 10¿ù ¹Ì±¹¿¡ º»»ç¸¦ µÐ °úÇÐÀÚ, ȯÀÚ, ÀÇ·á Á¦°ø¾÷ü¸¦ ´ëÇ¥ÇÏ´Â Á¶Á÷ÀÎ Personalized Medicine CoalitionÀº ȯÀÚ¿Í ÀÇ·áÁ¦µµ¿¡ ÀÌÀÍÀ» °¡Á®´ÙÁÖ´Â ¸ÂÃãÇü ÀÇ·áÀÇ ÀÌÇØ¿Í ä¿ëÀ» ÃËÁøÇϱâ À§ÇØ ¿©·¯ À¯ÇüÀÇ ¾Ï, À¯ÀüÀû Èñ¼ÒÁúȯ, ´Ù¾çÇÑ ¸¸¼ºÁúȯ°ú °¨¿°Áõ ȯÀÚ¸¦ ´ë»óÀ¸·Î 7¸¸ 5,000°³ ÀÌ»óÀÇ À¯ÀüÀÚ°Ë»ç Á¦Ç°°ú 300°³°¡ ³Ñ´Â °³º°È­ ÀǾàǰÀÌ ½ÃÀå¿¡ ³ª¼±´Ù°í ÃßÁ¤Çß½À´Ï´Ù. ¶ÇÇÑ, °³ÀÎ ¸ÂÃãÇü ÀǾàǰÀ» ¿ËÈ£ÇÏ´Â ¹Ì±¹ ±â¾÷ PMC(Personalized Medicine Coalition)¿¡ µû¸£¸é 2022³â¿¡´Â ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÇ ½Å¾à ½ÂÀÎ Áß °³ÀÎ ¸ÂÃãÇü ÀǾàǰÀÌ 34%¸¦ Â÷ÁöÇßÀ¸¸ç, Áö³­ 8³â°£ ½ÂÀÎµÈ ÀǾàǰ Áß ÃÖ¼Ò 25% ÀÌ»óÀ» Â÷ÁöÇß½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ¼¼°èÀÇ ¿ø¹ß¼º ´ãÁó¼º ´ã°ü¿° ½ÃÀå¿¡ ´ëÇÑ Á¶»ç ºÐ¼®À» ÅëÇØ ½ÃÀå Æ¯Â¡, °¢ Áö¿ª ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø, °æÀï ±¸µµ, ½ÃÀå ±âȸ ¹× Àü·« µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¸ñÂ÷

Á¦3Àå Ç¥ ¸ñ·Ï

Á¦4Àå ±×¸² ¸ñ·Ï

Á¦5Àå º¸°í¼­ ±¸¼º

Á¦6Àå ½ÃÀå Æ¯Â¡

Á¦7Àå ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦8Àå ¼¼°èÀÇ ¿ø¹ß¼º ´ãÁó¼º ´ã°ü¿° ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦9Àå ¼¼°èÀÇ ¿ø¹ß¼º ´ãÁó¼º ´ã°ü¿° ½ÃÀå ¼¼ºÐÈ­

Á¦10Àå ¿ø¹ß¼º ´ãÁó¼º ´ã°ü¿° ½ÃÀå : Áö¿ª°ú ±¹°¡ÀÇ ºÐ¼®

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦12Àå ¼­À¯·´ ½ÃÀå

Á¦13Àå µ¿À¯·´ ½ÃÀå

Á¦14Àå ºÏ¹Ì ½ÃÀå

Á¦15Àå ³²¹Ì ½ÃÀå

Á¦16Àå Áßµ¿ ½ÃÀå

Á¦17Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦18Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦19Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦20Àå °æÀï º¥Ä¡¸¶Å·

Á¦21Àå °æÀï ´ë½Ãº¸µå

Á¦22Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦23Àå ¿ø¹ß¼º ´ãÁó¼º ´ã°ü¿° ½ÃÀåÀÇ ÃÖ±Ù ¹ßÀü

Á¦24Àå ±âȸ¿Í Àü·«

Á¦25Àå ¿ø¹ß¼º ´ãÁó¼º ´ã°ü¿° ½ÃÀå : °á·Ð°ú Á¦¾È

Á¦26Àå ºÎ·Ï

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Primary biliary cholangitis (PBC) is a chronic, progressive liver disease that primarily affects the bile ducts within the liver. It is an autoimmune condition in which the body's immune system mistakenly attacks the small bile ducts, leading to inflammation and scarring. Over time, this damage impairs bile flow, causing a buildup of toxic substances that can lead to liver fibrosis, cirrhosis and ultimately liver failure.

The primary biliary cholangitis market consists of sales by entities (organizations, sole traders and partnerships) of primary biliary cholangitis drugs and treatments that are used to treat PBC. PBC predominantly affects middle-aged women, though it can also occur in men. It is typically diagnosed in individuals between the ages of 40 and 60, often following routine blood tests that indicate liver abnormalities.

The global primary biliary cholangitis market was valued at $733.21 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 5.00%.

Rising Demand for Personalized Medicine

During the historic period, the rising demand for personalized medicine supported the growth of the primary biliary cholangitis market. Personalized medicine tailors treatments based on genetic, molecular and clinical profiles, enabling more precise therapies for primary biliary cholangitis. Obeticholic acid (OCA) serves as a targeted alternative to traditional treatments like ursodeoxycholic acid (UDCA). New therapies, including fibrates and FXR (farnesoid X receptor) agonists, are being evaluated for specific patient groups. Pharmacogenomics enhances treatment by predicting efficacy, minimizing side effects and reducing trial-and-error prescribing. This approach optimizes outcomes by ensuring patients receive the most effective, individualized therapy. For example, in October 2022, the Personalized Medicine Coalition, a US-based organization that represents scientists, patients and providers, promoting the understanding and adoption of personalized medicine to benefit patients and the healthcare system, estimated that more than 75,000 genetic testing products and 300 personalized medicines are on the market for people with multiple types of cancers, genetic rare diseases and a range of chronic and infectious diseases. Additionally, in 2022, according to the Personalized Medicine Coalition (PMC), a US-based company that advocates for personalized medicine, personalized medicines will account for 34% of new drug approvals by the US Food and Drug Administration in 2022 and have accounted for at least 25% of approvals in each of the previous eight years. Therefore, the rising demand for personalized

Role Of Combination Therapy In Liver Disease Management

Major companies operating in the primary biliary cholangitis market are focusing on introducing innovative therapies such as combination therapy to enhance treatment efficacy and improve patient outcomes in liver cancer care. Combination therapy refers to the use of two or more treatments or drugs together to target a specific condition, enhancing the overall therapeutic effect. For example, in June 2024, Ipsen Biopharmaceuticals, Inc., a France-based biopharmaceutical company received U.S. Food and Drug Administration (FDA) approval for Ipsen's Iqirvo (elafibranor) 80 mg (miligram) tablets for treating primary biliary cholangitis (PBC). This drug is a first-in-class PPAR (peroxisome proliferator-activated receptor) treatment. It is intended for use in combination with ursodeoxycholic acid (UDCA) for adults who do not respond adequately to UDCA, or as a monotherapy for patients who cannot tolerate UDCA.

The global primary biliary cholangitis market is highly concentrated, with large players operating in the market. The top ten competitors in the market made up to 50.90% of the total market in 2023.

Primary Biliary Cholangitis Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global primary biliary cholangitis market as it emerges from the COVID-19 shut down.

Reasons to Purchase

Where is the largest and fastest-growing market for primary biliary cholangitis? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The primary biliary cholangitis market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider primary biliary cholangitis market; and compares it with other markets.

The report covers the following chapters

Markets Covered:

Table of Contents

1 Executive Summary

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

7 Major Market Trends

8 Global Primary Biliary Cholangitis Growth Analysis And Strategic Analysis Framework

9 Global Primary Biliary Cholangitis Market Segmentation

10 Primary Biliary Cholangitis Market, Regional and Country Analysis

11 Asia-Pacific Market

12 Western Europe Market

13 Eastern Europe Market

14 North America Market

15 South America Market

16 Middle East Market

17 Africa Market

18 Competitive Landscape and Company Profiles

19 Other Major And Innovative Companies

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

23 Recent Development In Primary Biliary Cholangitis Market

24 Opportunities And Strategies

25 Primary Biliary Cholangitis Market, Conclusions And Recommendations

26 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â